SCHEMBL5207058

SCHEMBL5207058

COc1cc2[nH]c(C)c(CC(=O)Nc3cc(C)ccc3C(=O)O)c2cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ GAA P10253 3/20 0.46
▸ POLB P06746 1/20 0.45
▸ LPAR1 Q92633 1/20 0.43
▸ AKR1C2 P52895 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MTNR1A P48039 1/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213791 0.88 POLB (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5214528 0.87 AKR1C2 (0.61) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5211697 0.83 MAPT (0.55) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5210674 0.82 MAPT (0.54) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5205838 0.78 AKR1C2 (0.61) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5274070 0.78 AKR1C2 (0.58) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5209238 0.77 AKR1C2 (0.59) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5208935 0.77 MEN1 (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5208570 0.77 AKR1C2 (0.59) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5211125 0.76 AKR1C2 (0.58) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 — — EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 — — US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 — — EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 MAPT 788/4885ALDH1A1 1116/4885MEN1 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback